Aclaris Therapeutics (NASDAQ:ACRS) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Aclaris Therapeutics (NASDAQ:ACRS) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.04, FiscalAI reports. The company had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.27 million. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%.

Aclaris Therapeutics Trading Down 1.9%

Shares of NASDAQ:ACRS traded down $0.07 on Thursday, hitting $3.61. 2,329,001 shares of the company’s stock were exchanged, compared to its average volume of 3,181,452. The firm’s 50-day moving average is $4.67 and its 200 day moving average is $4.54. Aclaris Therapeutics has a 1-year low of $2.10 and a 1-year high of $6.60.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Aclaris Therapeutics in a research note on Wednesday, October 28th. Craig Hallum set a $9.00 price objective on Aclaris Therapeutics in a research note on Wednesday, October 28th. Wall Street Zen upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, September 21st. Finally, Canaccord Genuity Group raised their target price on shares of Aclaris Therapeutics from $10.00 to $13.00 and gave the company a “buy” rating in a report on Friday, October 30th. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Aclaris Therapeutics currently has an average rating of “Buy” and a consensus price target of $11.33.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.